nivolumab + pazopanib

**Nivolumab + pazopanib** is an investigational combination regimen of two pharmaceutical agents: nivolumab, a fully human IgG4 monoclonal antibody targeting the programmed death-1 (PD-1) immune checkpoint, and pazopanib, a small molecule multi-targeted tyrosine kinase inhibitor (TKI) with activity primarily against vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit. Nivolumab acts as an immune checkpoint inhibitor, reversing T-cell suppression in the tumor microenvironment by blocking the PD-1 pathway, thus enhancing antitumor immune responses. Pazopanib inhibits tumor angiogenesis and cell proliferation via blockade of VEGFR and related kinases. The combination has been evaluated in clinical trials for advanced or metastatic renal cell carcinoma (RCC) and relapsed/metastatic sarcoma. Early trials showed some antitumor activity, but the regimen was associated with a high incidence of grade 3/4 toxicities, particularly hepatotoxicity, resulting in early trial closure for this combination and limited further development[1][3][5][7].

Brand names

Opdivo + Votrient

Other names

nivolumab and pazopanib